COPD experimental therapy 9MW1911 reduced moderate to severe exacerbations in a Phase 2a trial, showing a favorable safety ...

Bionews, Inc., the parent company of this site, has partnered with the following nonprofit advocacy organizations to help further the mission of ensuring that patients and caregivers are able to get ...